Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEVATE-PLUS: Acalabrutinib Tablet Bioavailability, PPI, and Food Effect Study
NCT04488016Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2020
- Primary completion
- Jan 2021
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of acalabrutinib tablet (Variant 1) in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (6 arms), sponsored by AstraZeneca. Primary endpoints: Maximum observed plasma concentration at Day 2, Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration at Day 2 and 1 more. Started Jun 2020; status: completed.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04488016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04488016.